Ligand Pharmaceuticals Inc LGND
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
Ligand Partner Travere Therapeutics Receives Full FDA Approval for FILSPARI® (sparsentan), the Only Non-Immunosuppressive Treatment that Significantly Slows Kidney Function Decline in IgA Nephropathy
-
Ligand to Present at H.C. Wainwright 26th Annual Global Investment Conference
-
Ligand Reports Second Quarter 2024 Financial Results
-
Ligand to Report Second Quarter 2024 Financial Results on August 6, 2024
-
Ligand to Acquire APEIRON Biologics AG for $100 Million
-
Ligand Pharmaceuticals Gets FDA OK for Viral Skin Infection Treatment
Trading Information
- Previous Close Price
- —
- Day Range
- —–—
- 52-Week Range
- —–—
- Bid/Ask
- — / —
- Market Cap
- —
- Volume/Avg
- — / —
Key Statistics
- Price/Earnings (Normalized)
- 20.85
- Price/Sales
- 13.11
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
Ligand Pharmaceuticals Inc is a biopharmaceutical company focused on developing and acquiring technologies that aid in creating medicine. The company has partnerships and license agreements with various pharmaceutical and biotechnology companies. Ligand's business model is based on drug discovery, early-stage drug development, product reformulation, and partnerships. The company's revenue consists of three primary elements: royalties from commercialized products, license and milestone payments, and sale of its trademarked Captisol material.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Core
- Total Number of Employees
- 58
- Website
- https://www.ligand.com
Comparables
Valuation
|
Metric
|
LGND
|
CRNX
|
CORT
|
|---|---|---|---|
Price/Earnings (Normalized) | 20.85 | — | 54.23 |
Price/Book Value | 2.27 | 4.85 | 7.69 |
Price/Sales | 13.11 | 2,523.62 | 8.54 |
Price/Cash Flow | 20.85 | — | 35.76 |
Price/Earnings
LGND
CRNX
CORT
Financial Strength
|
Metric
|
LGND
|
CRNX
|
CORT
|
|---|---|---|---|
Quick Ratio | 14.24 | 15.96 | 5.23 |
Current Ratio | 16.82 | 16.09 | 5.57 |
Interest Coverage | 29.70 | — | — |
Quick Ratio
LGND
CRNX
CORT
Profitability
|
Metric
|
LGND
|
CRNX
|
CORT
|
|---|---|---|---|
Return on Assets (Normalized) | 0.97% | −29.20% | 27.60% |
Return on Equity (Normalized) | 1.09% | −33.39% | 33.89% |
Return on Invested Capital (Normalized) | 0.30% | −35.10% | 30.18% |
Return on Assets
LGND
CRNX
CORT
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Novo Nordisk AS ADR
NVO
| Fhmczpnc | Qjk | $531.4 Bil | |||
| Vertex Pharmaceuticals Inc
VRTX
| Gprxrbpk | Vljcpwb | $119.5 Bil | |||
| Regeneron Pharmaceuticals Inc
REGN
| Gnlzkzyhb | Fwlhl | $114.9 Bil | |||
| Alnylam Pharmaceuticals Inc
ALNY
| Ygfwwmgdp | Lfftkn | $35.3 Bil | |||
| argenx SE ADR
ARGX
| Cdppnndyt | Mxcq | $32.0 Bil | |||
| BioNTech SE ADR
BNTX
| Pnjbpvj | Hgrl | $28.1 Bil | |||
| Moderna Inc
MRNA
| Mjxfxqyk | Kpj | $25.3 Bil | |||
| United Therapeutics Corp
UTHR
| Bzqllbw | Dps | $16.0 Bil | |||
| Biomarin Pharmaceutical Inc
BMRN
| Rgrxbnywl | Rzndgp | $13.4 Bil | |||
| Incyte Corp
INCY
| Krngvmfwl | Jmlbyrn | $12.7 Bil |
United States